EmpagliflozinSodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

Sponsor:

Vanderbilt University Medical Center

Code:

NCT07172971

Conditions

Duchenne Muscular Dystrophy (DMD)

Eligibility Criteria

Sex: Male

Age: 8 - 18

Healthy Volunteers: Not accepted

Interventions

SGLT-2 inhibitor

SGLT2 inhibitor

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Vanderbilt University Medical Center on 2026-08-24.